Treatment of Hyperreactive Airways Causing Productive Cough
Start with inhaled corticosteroids (ICS) as first-line therapy, and if the response is incomplete after initial treatment, step up the ICS dose and add a leukotriene inhibitor while reconsidering alternative diagnoses 1.
Initial Diagnostic Considerations
Before initiating treatment, you need to distinguish between two key conditions that present with airway hyperresponsiveness and cough:
- Cough Variant Asthma (CVA): Airway hyperresponsiveness WITH variable airflow obstruction
- Non-Asthmatic Eosinophilic Bronchitis (NAEB): Airway hyperresponsiveness WITHOUT variable airflow obstruction or bronchial hyperresponsiveness on testing
If spirometry and physical examination are non-diagnostic, perform bronchial challenge testing (methacholine inhalation test) to confirm airway hyperresponsiveness 1. Consider measuring non-invasive inflammatory markers (blood/sputum eosinophils, fractional exhaled nitric oxide [FeNO]) to support the need for corticosteroid treatment 1.
Recent evidence shows CVA patients have lower FeNO values than classic asthma patients (24.0 ppb vs 36.0 ppb), and FeNO has lower predictive value for positive bronchial challenge in chronic cough patients 2.
Treatment Algorithm
Step 1: Initiate ICS Therapy
- For CVA or asthma with cough: ICS as first-line treatment (Grade 1B) 1
- For NAEB: ICS as first-choice treatment (Grade 2B) 1
The evidence base for stepwise asthma treatment is very strong per GINA guidelines, though cough-specific studies are limited 1.
Step 2: If Incomplete Response
After reassessing for alternative causes of cough:
- Step up the ICS dose
- Add a leukotriene inhibitor (therapeutic trial)
- Consider adding beta-agonists in combination with ICS 1
This applies to both CVA/asthma (Grade 1B) and NAEB (Grade 2C) 1.
Step 3: Monitoring Response
Both CVA and classic asthma patients show significant improvement in large and small airway function after 4 weeks of anti-asthma therapy 2. The most valuable predictors of positive treatment response are:
- Improvement in FEV1 (≥90-110 ml improvement)
- Improvement in FEV1% (≥2.59-3.49% improvement) after bronchodilator testing at baseline 2
Key Mechanistic Insights
The productive cough in hyperreactive airways stems from two components 3:
- Transient/inducible hyperresponsiveness: Linked to airway inflammation, responds rapidly to ICS, more marked with indirect stimuli
- Persistent hyperresponsiveness: Related to structural airway remodeling, relatively refractory to ICS, reflected by methacholine responsiveness
Indirect bronchial provocation tests (exercise, mannitol) have a stronger relationship with steroid-sensitive inflammation compared to direct stimuli (methacholine), making them better markers for predicting ICS response 4.
Common Pitfalls to Avoid
- Don't assume all chronic productive cough is infection-related: Airway hyperresponsiveness causes productive cough through eosinophilic inflammation and bronchitis, not just infection 1
- Don't stop at normal spirometry: 30.4% of patients with asthma-compatible symptoms and normal spirometry have positive methacholine challenge tests 5
- Don't confuse NAEB with asthma: NAEB lacks the airway smooth muscle mast cell infiltration that causes bronchospasm in asthma, explaining why it presents primarily with cough rather than wheeze 1
- Reconsider alternative diagnoses before escalating therapy, as the evidence for NAEB treatment is based on small studies (Grade 2C) 1
Special Consideration
The epithelium plays a critical role in driving inflammation that mediates airway hyperresponsiveness through release of thymic stromal lymphopoietin and IL-33, which upregulate type 2 cytokines and promote eosinophilia 6. This underscores why anti-inflammatory therapy with ICS is the cornerstone of treatment.